NASDAQ · Medical Devices · USD
NeuroOne Medical Technologies Corporation (NMTC) Stock Analysis
NeuroOne Medical Technologies Corporation (NMTC) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NMTC Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.97
- Previous Close
- $0.98
- Day's Range
- 0.91–0.97
- 52-Week Range
- 0.91–6.12
- Volume
- 36.64K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.76
Valuation
- Market Cap
- $8.30M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.67
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.99
Financials (FY)
- Revenue (FY)
- $9.10M+163.47%
- Net Income (FY)
- −$3.61M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −59.71%
- Shares Outstanding
- 9.11M
- 1-Year Return
- −81.46%
Dividend and dates
- Avg Volume
- 338.19K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NMTC closed at $0.91, −81.46% over 1 year.
NeuroOne Medical Technologies Corporation (NMTC) has a market capitalization of $8.30M.
In fiscal 2025, NMTC reported revenue of $9.10M.
NMTC Stock Return by Calendar Year
NeuroOne Medical Technologies Corporation (NMTC) return since Mar 2018: what $10,000 became
- 1 year
- $10,000 $1,854
- −81.46%
- 5 years
- $10,000 $518
- −94.82%
- Since Mar 2018
- $10,000 $126
- −98.74%
If you had invested $10,000 in NeuroOne Medical Technologies Corporation (NMTC) at the close on March 15, 2018, the earliest close on record here, it would have been worth $126 at the close on October 21, 2026: −98.74% in total, −39.86% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −79.96% |
| 2025 | −8.23% |
| 2024 | −47.72% |
| 2023 | +31.67% |
| 2022 | −38.14% |
| 2021 | −58.81% |
| 2020 | −34.03% |
| 2019 | −57.19% |
| 2018 (partial year) | +38.31% |
As of October 21, 2026.
NMTC Revenue and Earnings by Fiscal Year
FY ends September| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $9.10M | −$3.61M | −39.6% |
| 2024 | $3.45M | −$12.32M | −356.7% |
| 2023 | $1.95M | −$11.86M | −607.4% |
| 2022 | $171.17K | −$10.00M | −5,842.0% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $9.10M | $5.14M | −$4.23M | −$3.61M | −39.6% |
| 2024 | $3.45M | $1.08M | −$11.89M | −$12.32M | −356.7% |
| 2023 | $1.95M | $456.52K | −$11.96M | −$11.86M | −607.4% |
| 2022 | $171.17K | −$70.79K | −$10.03M | −$10.00M | −5,842.0% |
Annual figures as reported, in the company's reporting currency. As of September 30, 2025.
NMTC Valuation vs Medical Devices Median
Median of 145 stocks| Metric | NMTC | Medical Devices median | vs median |
|---|---|---|---|
| P/S ratio | 0.67 | 2.53 | 0.3x the median |
| Profit margin | −59.71% | −14.78% | 44.9 pts below |
Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
YahooNeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
YahooNeuroOne Medical Technologies Reports Preliminary Q4 Sales ~$3.8M , Up 38.4% YoY; Sees FY26 Sales Of ~$10.5M, Up 15.6% YoY; Includes September Purchase Order Of $4.5M
BenzingaNeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement
YahooNeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter
BenzingaMaxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5
Benzinga
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Medical Devices Stocks
Abbott Laboratories
$173.92B
MDTMedtronic plc.
$119.00B
SYKStryker Corporation
$114.15B
BSXBoston Scientific Corporation
$64.33B
EWEdwards Lifesciences Corporation
$50.95B
GEHCGE HealthCare Technologies Inc.
$31.17B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B




